Frontierby eninvs

Language: EN · RU

← Region

Sun Pharmaceutical Industries (SUNPHARMA) USD

At a glance: strengths & risks
✓Revenue growing (+10% y/y, Q1 2026)✓Profit growing (+27% y/y, Q1 2026)✓Margins improving (29%→33%, Q1 2026)✓Net cash balance sheet

Sector: Pharmaceuticals

IN_SUNPHARMA

Price chart

1 931.7 INRDay 0.14%
1 931.71 931.031 930.351 929.671 929Two-point segment from the displayed day change; full history unavailable.min 1 929 · max 1 931.7

Key metrics

Net debt (table and EV/EBITDA): |short-term borrowings| + |long-term borrowings| + |other financial liabilities| when extracted + |non-controlling interest| when extracted − |cash and equivalents|; amounts in millions of the reporting currency.

Market

Price
1 931.7 INR · 0.14%
Market cap
48.8 bn USD

Growth

Δ revenue y/y
2.3%
Δ EBITDA y/y
-2.0%

Multiples

P/E (LTM)
38.8x
P/B (FY)
5.5x
P/E (ann.)
39.1x
EV/EBITDA (LTM)
—

Cash return

Dividend yield
—
FCF yield (LTM)
-71.2%

Value creation

fundamental value/yr, % of market cap
Value created / year
-56.0%
↓ details

Liquidity

Daily turnover
—

Shares: connector/market_inputs

Amounts: USD (converted) · As reported
Converted modes use NBK / ECB-linked rates: balance sheet date for BS items, period average for P&L and cash flow (see filing row evidence). As reported keeps each row in its filing currency.

Financial results

Monetary columns are in B USD, one decimal; scale (K/M/B/T) keeps values readable. For the period (default) shows P&L and cash flow for that row’s reporting window: quarterly amounts when the feed uses quarter-duration facts (typical US 10-Q revenue and income), quarterly cash flows after stripping YTD where only cumulative tags exist, and an implied Q4 on 31 Dec FY rows (P&L: FY minus Q1–Q3; operating / investing cash flow: FY 12m minus 9M YTD to 30 Sep when sourced from SEC builder evidence) so they match 10-Q scale. Some issuers still use cumulative YTD minus the prior row in the same calendar year. As reported shows values stored on each row (e.g. full-year on FY). Balance sheet is always as reported. Source JSON may use millions etc.; conversion uses amounts_unit per row.

DatePeriodStatusRevenueB USDOperating profitB USDD&AB USDEBITDAB USDNet profitB USDOperating CFB USDCapex + M&AB USDAssetsB USDEquityB USDROE (annualized)Net debtB USDSource
2026-06-30Q2 2026 (3M)PARTIAL1.6
y/y 2.3%
0.4
y/y -2.0%
0.1
y/y -2.0%
0.5
y/y -2.0%
0.3
y/y 18.0%
———
y/y —
8.9
y/y 4.9%
14.1%≈ -56.9—
2026-03-31FY 2026 (12M)OK—
y/y 5.6%
—
y/y 1.9%
—
y/y 7.6%
—
y/y 2.9%
—
y/y -0.9%
——11.6
y/y 7.6%
8.9
y/y 5.4%
14.3%-56.9—
2025-12-31Q4 2025 (3M)PARTIAL1.8
y/y 8.2%
0.5
y/y 9.1%
0.1
y/y —
0.5
y/y 28.8%
0.4
y/y 11.0%
———
y/y —
8.7
y/y 7.3%
5.8%≈ -75.7—
2025-09-30Q3 2025 (3M)OK1.7
y/y 5.1%
0.4
y/y 2.0%
0.0
y/y —
0.4
y/y 9.3%
0.4
y/y -1.0%
——11.7
y/y 11.1%
8.8
y/y 6.3%
16.7%-75.7Link
2025-06-30Q2 2025 (3M)PARTIAL1.6
y/y 5.3%
0.4
y/y 8.5%
0.1
y/y —
0.5
y/y 31.1%
0.3
y/y -22.3%
———
y/y —
8.4
y/y 5.0%
12.5%≈ -84.0—
2025-03-31FY 2025 (12M)OK—
y/y 5.0%
—
y/y 15.8%
—
y/y -2.9%
—
y/y 12.1%
—
y/y 10.0%
——10.8
y/y 5.1%
8.5
y/y 10.7%
15.3%-84.0—
2024-12-31Q4 2024 (3M)PARTIAL1.6
y/y 8.8%
0.4
y/y 28.5%
—
y/y —
0.4
y/y 28.5%
0.3
y/y 13.3%
———
y/y —
8.1
y/y 6.7%
5.6%≈ -69.3Link
2024-09-30Q3 2024 (3M)OK1.6
y/y 7.6%
0.4
y/y 21.8%
—
y/y —
0.4
y/y 21.8%
0.4
y/y 26.3%
——10.5
y/y 10.0%
8.3
y/y 8.9%
17.8%-69.3Link
2024-06-30Q2 2024 (3M)PARTIAL1.5
y/y —
0.4
y/y —
—
y/y —
0.4
y/y —
0.3
y/y —
———
y/y —
8.0
y/y —
17.4%≈ -64.4Link
2024-03-31FY 2024 (12M)OK—
y/y 9.4%
—
y/y 11.9%
—
y/y 0.2%
—
y/y 9.4%
—
y/y 12.1%
——10.3
y/y 4.4%
7.6
y/y 12.1%
15.1%-64.4—
2023-12-31Q4 2023 (3M)PARTIAL1.5
y/y —
0.3
y/y —
—
y/y —
0.3
y/y —
0.3
y/y —
———
y/y —
7.6
y/y —
5.3%≈ 15.7Link
2023-09-30Q3 2023 (3M)OK1.5
y/y —
0.3
y/y —
—
y/y —
0.3
y/y —
0.3
y/y —
——9.6
y/y —
7.6
y/y —
16.0%≈ 15.7Link
2023-03-31FY 2023 (12M)OK5.3
y/y —
1.1
y/y —
0.3
y/y —
1.4
y/y —
1.0
y/y —
0.6-20.99.8
y/y —
6.8
y/y —
—15.7—

Revenue & EBITDA

RevenueEBITDA

Quarterly values (INR mln)

05001 0001 5002 0002024 q12024 q22024 q32024 q42025 q12025 q22025 q32025 q42026 q12026 q2

Year-over-year change

-10%0%10%20%30%2024 q12024 q22024 q32024 q42025 q12025 q22025 q32025 q42026 q12026 q2

Cash flow

Net debt / cash (INR mln)

-100 000-80 000-60 000-40 000-20 00002024 q22024 q32024 q42025 q12025 q22025 q32025 q42026 q12026 q22026 q4

Profit and cash

Profit is cash-backed
In a typical year of 2022–2026 operating cash flow came to 1.27x of reported net profit; after capex, 1.04x.
year20222023202420252026
cash flow / profit2.75x0.58x1.27x1.29x1.08x
accruals, % of assets—4.3%-3.0%-3.4%-0.9%
net debt / EBITDA -0.3x · capex 0.9x of depreciation
Read from the reported annual statements: cash flow / profit is the median of the yearly operating cash flow over net profit for the years shown; accruals are (profit − operating cash flow) / assets, the classic gap between what was booked and what was collected. A gap can be growth in working capital, capitalised costs, revaluations or profit from associates — the panel points at it, the statements explain it. Not investment advice.

Fundamental value creation

Value the company creates per year, as a % of market cap

Value created per year: -56.0%

How this was calculated
1. EBITDA growth (latest quarter YoY, annualised)
[EBITDA latest qtr − EBITDA year-ago qtr] × annualisation X (2026-06-30 vs 2025-06-30)
= (463 − 473) × 3.87
-37
2. Current EV/EBITDA (LTM)
(Market cap + Net debt) ÷ EBITDA (LTM)
= (48 802 + -56 889) ÷ 1 796
0.0x
3. Target multiple
(Current EV/EBITDA + 11) ÷ 2
= (0.0 + 11) ÷ 2
5.5x
4. Cash flow (balance method, LTM)
Net-debt reduction + dividends + buybacks − equity issuance
= -27 102 + 0 + 0 − 0
-27 102
5. Value created per year
(EBITDA growth × Target multiple + Cash flow − Dilution) ÷ Market cap
= (-37 × 5.5 + -27 102) ÷ 48 802
-56.0%

Amounts in millions of the reporting currency. EBITDA growth is the latest quarter vs the same quarter a year ago, annualised.

Caveats:

  • FCF (LTM) approximated by latest FY (ended 2026-03-31, before the latest reported period 2026-06-30)
  • dividends/buybacks not in data - balance cash flow uses net-debt change only

Revenue growth & acceleration

Growth steady →
Last-year revenue growth +12% vs +9% the year before — a +2.9 pp move. 3-year CAGR +10%.
revenue growth by year: 2024 +10% · 2025 +9% · 2026 +12%
The growth-acceleration signal behind the GARP+acceleration strategy — it favours companies whose revenue growth is speeding up and flags those slowing down (the second derivative of growth).

Dividends

No dividend rows found for this issuer (checked: Yahoo Finance (ex-div)).

Reporting forms detected in loaded periods: ✓ ✓ ✓ (Balance sheet / Profit or loss (P&L) / Cash flows)

Financial results, valuation multiples (P/E, P/B, EV/EBITDA), profitability and dividend yield of Sun Pharmaceutical Industries (SUNPHARMA) — from primary filings.

Frequently asked questions

What is Sun Pharmaceutical Industries (SUNPHARMA)'s P/E ratio?
Sun Pharmaceutical Industries (SUNPHARMA) trades at a P/E of 38.8x (price to trailing 12-month earnings).
What is Sun Pharmaceutical Industries (SUNPHARMA)'s P/B ratio?
Sun Pharmaceutical Industries (SUNPHARMA) trades at a P/B of 5.5x.
What is Sun Pharmaceutical Industries (SUNPHARMA)'s return on equity (ROE)?
Sun Pharmaceutical Industries (SUNPHARMA)'s ROE is 14.1%.
What is Sun Pharmaceutical Industries (SUNPHARMA)'s market capitalization?
Sun Pharmaceutical Industries (SUNPHARMA)'s market cap is 48.8 bn USD.

See also: The Cheapest Stocks in the World (2026): What Value Investing Says About Buying Cheap · global valuation map